The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Prognostic factors in patients receiving neoadjuvant 5‐fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)
Abstract
OBJECTIVE: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. METHODS: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. RESULTS: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb) <4.0 g/dl (vs. ≥ 4.0 g/dl; HR 2.29, p = 0.0005) were associated with a poor prognosis. Four independent prognostic factors were identified by multivariate analysis of both preoperative and postoperative factors: pathological curability B (pB; R0 with stage IV or pD < pN) or pC [microscopic or macroscopic residual tumor (R1/R2)] [vs. pA (R0); HR 1.93, p = 0.015], pathological stage N1 (vs. pN0; HR 3.86, p = 0.0012), cT3 (vs. cT1-2; HR 2.80, p = 0.0073), and serum Alb <4.0 g/dl (vs. ≥ 4.0 g/dl; HR 2.03, p = 0.0069). CONCLUSIONS: Preoperative cT stage, Alb, and postoperative pathological findings are independent prognostic factors for patients undergoing neoadjuvant chemotherapy for advanced thoracic esophageal SCC. This analysis may aid in stratification according to individual patient risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hypoalbuminemia often proves to be a strong independent risk factor for failure of chemotherapy and for mortality.
“Hypoalbuminemia often proves to be a strong independent risk factor for failure of chemotherapy and for mortality.138, 140, 141, 142, 143, 144, 145, 146”
From Hypoalbuminemia: Pathogenesis and Clinical Significance (2019) · cites this paper as [140]
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
TNM Classification of Malignant Tumours
Hermanek, P., & Sobin, L. H. (1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,074
[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients].
Onodera, T., Goseki, N., & Kosaki, G. (1984) · PubMed · Cited by 1,688
Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A. P., & Gebski, V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70142-5 · Cited by 1,641
Ando, N., Kato, H., Igaki, H., Shinoda, M., Ozawa, S., Shimizu, H., Nakamura, T., Yabusaki, H., Aoyama, N., Kurita, A., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2049-9 · Cited by 1,429
Self-citationRoxburgh, C. S. D., & McMillan, D. C. (2009) · Future Oncology · doi:10.2217/fon.09.136 · Cited by 1,004
Berger, A. C., Farma, J. M., Scott, W. J., Freedman, G. M., Weiner, L. M., Cheng, J. D., Wang, H., & Goldberg, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.017 · Cited by 504
McMillan, D. C., Watson, W. S., O'Gorman, P., Preston, T., Scott, H. R., & McArdle, C. S. (2001) · Nutrition and Cancer · doi:10.1207/s15327914nc392_8 · Cited by 461
Fujita, H., Kakegawa, T., Yamana, H., Shima, I., Toh, Y., Tomita, Y., Fujii, T., Yamasaki, K., Higaki, K., Noake, T., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199511000-00008 · Cited by 396
Nakamura, K., Kato, K., Igaki, H., Ito, Y., Mizusawa, J., Ando, N., Udagawa, H., Tsubosa, Y., Daiko, H., Hironaka, S., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt061 · Cited by 289
Self-citationEvaluation of neck lymph node dissection for thoracic esophageal carcinoma
Kato, H., Watanabe, H., Tachimori, Y., & Iizuka, T. (1991) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(91)91008-j · Cited by 268
Kaklamanos, I. G., Walker, G. R., Ferry, K., Franceschi, D., & Livingstone, A. S. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.078 · Cited by 236
Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Reynolds, J. V., Muldoon, C., Hollywood, D. P., Ravi, N., Rowley, S. P., O'Byrne, K. J., Kennedy, J., & Murphy, T. J. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000254367.15810.38 · Cited by 161
Vallböhmer, D., Hölscher, A. H., DeMeester, S. R., DeMeester, T. R., Salo, J., Peters, J. H., Lerut, A., Swisher, S. G., Schröder, W., Bollschweiler, E., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181fb8dde · Cited by 159
Zhang, S.-M., Yang, H., Luo, K. J., Huang, Q., Chen, J. Y., Yang, F., Cai, X. L., Xie, X., Liu, Q., Bella, A. É., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.666 · Cited by 147
Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern
Abeler, V. M., Vergote, I. B., Zzrstad, K. E. K., & Trope, C. G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961015)78:8 · Cited by 144
Parameters Linked to Ten-Year Survival in Japan of Resected Esophageal Carcinoma
Iizuka, T., Isono, K., Kakegawa, T., & Watanabe, H. (1989) · CHEST Journal · doi:10.1378/chest.96.5.1005 · Cited by 124
van Hagen, P., Wijnhoven, B. P. L., Nafteux, P. R., Moons, J., Haustermans, K. M., Hertogh, G. D., van Lanschot, J. J. B., & Lerut, A. (2012) · British journal of surgery · doi:10.1002/bjs.8968 · Cited by 111
Zhu, Z., Chen, H., Yu, W., Fu, X., Xiang, J., Li, H., Zhang, Y., Sun, M., Qiao, W., Zhao, W., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3665-y · Cited by 86
Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma
Feng, J., & Chen, Q. (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s56159 · Cited by 81
Matsuda, S., Takeuchi, H., Kawakubo, H., Fukuda, K., Nakamura, R., Takahashi, T., Wada, N., Saikawa, Y., Omori, T., & Kitagawa, Y. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3857-5 · Cited by 80
Self-citationNoble, F., Hopkins, J. C. A., Curtis, N. J., Kelly, J. J., Bailey, I. S., Byrne, J. P., Bateman, A. C., Bateman, A. R., & Underwood, T. (2013) · Medical Oncology · doi:10.1007/s12032-013-0596-6 · Cited by 46
Japanese Society for Esophageal Diseases (2004) · Esophagus · doi:10.1007/s10388-004-0018-0 · Cited by 28
Surgical treatment of advanced carcinoma of the esophagus.
Abe, S., Tachibana, M., Shimokawa, T., Shiraishi, M., & Nakamura, T. (1989) · PubMed · Cited by 12
Flagged first, then by citations
Cited by
Sorted by citations
Hypoalbuminemia: Pathogenesis and Clinical Significance
Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1451 · Cited by 1,448
Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer
Kataoka, K., Takeuchi, H., Mizusawa, J., Igaki, H., Ozawa, S., Abe, T., Nakamura, K., Kato, K., Ando, N., & Kitagawa, Y. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001828 · Cited by 213
Self-citationYamamoto, S., Kato, K., Daiko, H., Kojima, T., Hara, H., Abe, T., Tsubosa, Y., Nagashima, K., Aoki, K., Mizoguchi, Y., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0189 · Cited by 68
Self-citationNomura, M., Kato, K., Ando, N., Ohtsu, A., Muro, K., Igaki, H., Abe, T., Takeuchi, H., Daiko, H., Gotoh, M., et al. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx040 · Cited by 42
Self-citationOtowa, Y., Nakamura, T., Yamamoto, M., Kanaji, S., Matsuda, Y., Matsuda, T., Oshikiri, T., Sumi, Y., Suzuki, S., & Kakeji, Y. (2017) · Diseases of the Esophagus · doi:10.1093/dote/dox107 · Cited by 33
Yokota, T., Igaki, H., Kato, K., Tsubosa, Y., Mizusawa, J., Katayama, H. G., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0899-z · Cited by 32
Self-citationSugimura, K., Miyata, H., Shinno, N., Ushigome, H., Asukai, K., Yanagimoto, Y., Hasegawa, S., Takahashi, Y., Yamada, D., Yamamoto, K., et al. (2019) · Oncology · doi:10.1159/000502342 · Cited by 25
Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer
Hou, S., Pan, Z., Hao, X., Hang, Q., & Ding, Y. (2021) · Cancers · doi:10.3390/cancers13205162 · Cited by 24
Prognostic value of hypoalbuminemia at diagnosis in de novo non-M3 acute myeloid leukemia
Wang, N., Desai, A. P., Ge, B., Li, W., Jin, X., Bai, H., Yu, K., & Ye, H. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1686499 · Cited by 22
Stage‐directed individualized therapy in esophageal cancer
Goense, L., van Rossum, P. S. N., Kandioler, D., Ruurda, J. P. H., Goh, K., Luyer, M. D. P., Krasna, M. J., & van Hillegersberg, R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13113 · Cited by 21
Tsou, Y., Liang, K., Lin, W., Chang, H., Tseng, C., & Yeh, C. (2017) · Oncotarget · doi:10.18632/oncotarget.16253 · Cited by 16
Furuta, M., Yokota, T., Tsushima, T., Todaka, A., Machida, N., Hamauchi, S., Yamazaki, K., Fukutomi, A., Kawai, S., Kawabata, T., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz089 · Cited by 14
Self-citationKubo, N., Ohira, M., Tamura, T., Sakurai, K., Toyokawa, T., Tanaka, H., Yashiro, M., Yamashita, Y., & Hirakawa, K. (2016) · Esophagus · doi:10.1007/s10388-016-0548-2 · Cited by 13
Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma
Oguma, J., Ozawa, S., Kazuno, A., Nitta, M., Ninomiya, Y., & Kajiwara, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.7666 · Cited by 13
Oguma, J., Ozawa, S., Koyanagi, K., Kazuno, A., Yamamoto, M., Ninomiya, Y., & Yatabe, K. (2019) · Esophagus · doi:10.1007/s10388-019-00679-8 · Cited by 13
Tooth Loss Predicts Long-Term Prognosis of Esophageal Cancer After Esophagectomy
Miura, S., Nakamura, T., Hasegawa, T., Miura, Y., Takiguchi, G., Urakawa, N., Hasegawa, H., Yamamoto, M., Kanaji, S., Matsuda, Y., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07903-w · Cited by 13
Enteral Nutritional Support in Patients Undergoing Chemoradiotherapy for Esophageal Carcinoma
Wang, B., Jiang, X., Tian, D., & Geng, W. (2020) · Future Oncology · doi:10.2217/fon-2020-0181 · Cited by 13
Honma, Y., Hokamura, N., Nagashima, K., Sudo, K., Shoji, H., Iwasa, S., Takashima, A., Kato, K., Hamaguchi, T., Boku, N., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11748 · Cited by 10
Self-citationJakubauskas, M., Jakubauskiene, L., Leber, B., Horvath, A., Strupas, K., Stiegler, P., & Schemmer, P. (2023) · Nutrients · doi:10.3390/nu15051117 · Cited by 9
Kanda, M., Koike, M., Iwata, N., Shimizu, D., Tanaka, C., Hattori, N., Hayashi, M., Yamada, S., Omae, K., Nakayama, G., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0546 · Cited by 9
Non-curative resection for surgical T4b esophageal cancer: esophagectomy or non-esophagectomy?
Fujii, Y., Daiko, H., Kubo, K., Kanematsu, K., Utsunomiya, D., Kurita, D., Ishiyama, K., & Oguma, J. (2023) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-023-02940-2 · Cited by 8
Shi, Y. X., Xu, J., Wang, Y., Tang, J., Zhang, C., Lv, W., & Hu, J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.02.25 · Cited by 8
Hara, H., Mizusawa, J., Hironaka, S., Kato, K., Daiko, H., Abe, T., Nakamura, K., Ando, N., & Kitagawa, Y. (2020) · Esophagus · doi:10.1007/s10388-020-00752-7 · Cited by 8
Self-citationResearch progress of sintilimab in the treatment of cancer (Review)
Wu, Y., & Shao, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.14986 · Cited by 7
Okunaka, M., Kotani, D., Fujiwara, H., Sato, K., Fujiwara, N., Mishima, S., Sakashita, S., Yoshino, T., Fujita, T., & Kojima, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241229432 · Cited by 7
Oguma, J., Ishiyama, K., Kurita, D., Kanematsu, K., Fujii, Y., Kubo, K., Yamamoto, S., Honma, Y., Kato, K., & Daiko, H. (2021) · Esophagus · doi:10.1007/s10388-021-00891-5 · Cited by 7
Self-citationKonishi, H., Fujiwara, H., Shiozaki, A., Shoda, K., Kosuga, T., Kubota, T., Okamoto, K. K., & Otsuji, E. (2018) · Anticancer Research · doi:10.21873/anticanres.12317 · Cited by 7
Kitani, M., Yamagata, Y., Tanabe, A., Yagi, K., Aikou, S., Kiyokawa, T., Nishida, M., Yamashita, H., Mori, K., Nomura, S., et al. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-1023-1 · Cited by 6
Lin, D., Ma, L., Ye, T., Pan, Y., Shao, L., Song, Z., Jiang, S., Chen, H., & Xiang, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.19 · Cited by 5
Tamba, M., Osumi, H., Ogura, M., Fukuoka, S., Okamura, A., Kanamori, J., Imamura, Y., Takahari, D., Yoshino, K., Udagawa, S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14011-4 · Cited by 3
The underlying metabolism of hypoalbuminemia and its clinical effects
Soeters, P. B., & de Leeuw, P. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820205-0.00010-4 · Cited by 3
Miyawaki, Y., Hirasaki, M., Kamakura, Y., Kawasaki, T., Baba, Y., Sato, T., Yamasaki, S., Fukushima, H., Uranishi, K., Makino, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11252-y · Cited by 2
Li, L.-Y., Zhang, M., Ying, W., Zhang, W., Jiang, W., Xiong, T.-J., Wang, F., & Fu, Z. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i8.108484 · Cited by 1
Kanda, M., Shimizu, D., Miyata, K., Maeda, O., Tanaka, C., Inokawa, Y., Hattori, N., Hayashi, M., Ando, M., Kuwatsuka, Y., et al. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100853 · Cited by 1
Electrolytes and Nutritional Element Assessment among Iraqi Cancer Patients Receiving Chemotherapy
Abdulrahman, M. S., El-Yassin, H. D., & Alwan, N. A. S. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.5426
Miyawaki, Y., Hirasaki, M., Kamakura, Y., Kawasaki, T., Baba, Y., Sato, T., Yamasaki, S., Fukushima, H., Uranishi, K., Makino, Y., et al. (2024) · medRxiv · doi:10.1101/2024.09.07.24313244
Metadata
- Authors
- Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y.
- Affiliations
- Shizuoka Cancer Center (JP)
- International Goodwill Hospital (JP)
- Aichi Cancer Center (JP)
- National Cancer Center Hospital (KR)
- National Cancer Centre Japan (JP)
- Keio University (JP)
- ORCID
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 89
- Issue
- 3
- Pages
- 143-151
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2053054248
- Cited by
- 36
- References
- 24
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 2 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 6 · 2016: 4 · 2015: 1
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- esophageal squamous cell carcinoma, neoadjuvant chemotherapy, 5-fluorouracil, cisplatin, prognostic factors, esophagectomy, lymph node dissection, serum albumin, pathological stage, clinical T stage, residual tumor
- MeSH terms
- Esophageal Squamous Cell Carcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Female, Fluorouracil, Humans, Japan, Male, Middle Aged, Neoplasm Staging, Prognosis, Risk Factors, Serum Albumin, Esophagectomy, Treatment Outcome, Chemotherapy, Adjuvant, Neoplasm, Residual, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
